Abbvie Inc (ABBV) Stock Price, Quote & News

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 847 932 7900

Website: www.abbvie.com

Address:

1 North Waukegan Road, North Chicago, United States

dewmoore Feb. 1 at 1:19 PM

$SLS Happy February 1: The 'Godzilla' Math is officially locked. 🦖📈 Enrollment ended April '24. We are now at 22 MONTHS—officially beating the Phase 2 record. Since only 72 have died, the only way we fail is if the other 54 died over the weekend. Spoilers: THEY DIDN'T! The IDMC is in the hot seat this week or next week! Under the new Jan '26 FDA rules, if they see this 'overwhelming' efficacy (likely a 63:9 split), they MUST recommend stoppage. Ignoring this creates a massive legal liability & standard-of-care trap! The shorts are trapped in a 42M share hole with the 'Death Clock' stopped. This is our month. $SLS #AML #GPS #ShortSqueeze $ATYR $MRK $ABBV If you have NOT read this on REDDIT -- you should on your Sunday DD -- Let's make a lot of money gang!!!!!! https://www.reddit.com/r/TheRaceTo10Million/comments/1qsbg5l/sls_to_crown_hundreds_of_millionaires_in_february/

3 · Reply

crtlabz Feb. 1 at 2:53 AM

$ABBV pipeline and growth accelerating. Been here 17y and don't mind the income. Divvy could be better, but better fundementals are the focus.

1 · Reply

DM1963 Jan. 31 at 6:44 PM

$ABBV Wow this stock was 60 during Covid expectations high would be nice to see them lower

0 · Reply

JFDI Jan. 30 at 8:44 PM

$ABBV

0 · Reply

ChessGM Jan. 30 at 7:59 PM

$ABBV https://youtu.be/h-s8MagQo1k. My focus list for stocks reporting earnings next week.

0 · Reply

taxplanr Jan. 30 at 5:49 PM

$ABBV not a bad yield for $110

0 · Reply

Sunny3999 Jan. 30 at 2:10 PM

$PMN fast track designation and DSMB approval and with this news $175 MILLION in the pocket ready to fly 🛫🚀 https://www.promisneurosciences.com/news-media/press-releases/detail/261/promis-neurosciences-announces-up-to-175-million-private $ABBV $CELG $JNJ $PFE

0 · Reply

Sunny3999 Jan. 30 at 1:13 PM

$PMN Boom 💥 News with news $175 million private placement https://www.promisneurosciences.com/news-media/press-releases/detail/261/promis-neurosciences-announces-up-to-175-million-private $ABBV $BMY $MRK $SNY

0 · Reply

dogDazeSummer Jan. 29 at 10:55 PM

$MLTX $IFRX The future kings of HS both looking tired of dropping. Exhausted sellers and now time to decide which BP is gonna gobble. 2 very important and completely independent MOA’s, no winner takes all with this sneaky disease. $ABBV $PFE $MRK

1 · Reply

scottybebs Jan. 29 at 9:15 PM

$ABBV what was that close!?

1 · Reply

Wall Street Week Ahead

AMD AMGN AMZN BE DIS FOF GOOG

Jan 29, 2026, 10:30 PM EST - 2 days ago

Harbor Small Cap Growth Fund Q4 2025 Portfolio Performance

ABVX CVLT FIX FTAI GKOS GMAB HLI

Jan 29, 2026, 10:10 AM EST - 2 days ago

10 Highest Rated Dividend Kings For Generations Of Income

ABM ABT ADM BDX BKH KMB KO

Jan 29, 2026, 8:00 AM EST - 3 days ago

AbbVie Launches Love in Mind™ to Spotlight the Emotional Impact of Migraine on Romantic Relationships

Jan 28, 2026, 8:00 AM EST - 4 days ago

Allergan Aesthetics Unveils New Data Across Facial Injectables On-Market and Emerging Portfolio at IMCAS 2026 Showcasing Enduring Strength in Advancing Aesthetics Medicine

Jan 27, 2026, 4:52 PM EST - 4 days ago

US Medicare names Eli Lilly, Pfizer and AbbVie drugs for next Medicare price talks

LLY PFE

Jan 27, 2026, 9:34 AM EST - 4 days ago

The AbbVie Foundation Is Now Accepting Applications to Participate in the 2026 AbbVie Foundation Health Equity Accelerator

Jan 25, 2026, 10:11 PM EST - 6 days ago

Best Dividend Kings: January 2026

ABM ABT ADM ADP AWR BDX BKH

$AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)$

Jan 16, 2026, 1:43 PM EST - 15 days ago

AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Jan 16, 2026, 1:35 PM EST - 15 days ago

Genmab and AbbVie's blood cancer drug fails to improve survival in late-stage study

GMAB

Jan 14, 2026, 5:45 PM EST - 17 days ago

AbbVie Inc. (ABBV) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 14, 2026, 2:01 PM EST - 17 days ago

AbbVie plans to build out its presence in obesity market

Jan 13, 2026, 7:22 AM EST - 19 days ago

AbbVie reaches 3-year deal with White House to lower drug prices

Jan 13, 2026, 5:24 AM EST - 19 days ago

AbbVie Strikes a $100 Billion Deal With Trump. How the Drugmaker Will Dodge Tariffs.

Jan 12, 2026, 7:03 PM EST - 19 days ago

AbbVie Strikes $100 Billion Investment Deal With Trump, Will Lower Medicaid Prices

Jan 12, 2026, 6:57 PM EST - 19 days ago

Abbvie, US reach agreement to cut drug prices

Jan 12, 2026, 6:30 PM EST - 19 days ago

AbbVie and Trump Administration Reach Agreement to Improve Access and Affordability for Americans

Jan 12, 2026, 7:39 AM EST - 20 days ago

AbbVie, RemeGen partner on experimental solid tumor treatment

Jan 12, 2026, 7:30 AM EST - 20 days ago

AbbVie and RemeGen Announce Exclusive Licensing Agreement to Develop A Novel Bispecific Antibody for Advanced Solid Tumors

Jan 12, 2026, 6:00 AM EST - 20 days ago

AbbVie to Acquire Arizona Manufacturing Facility, Further Strengthening Manufacturing Capabilities in the United States

WST

Jan 12, 2026, 6:00 AM EST - 20 days ago

West Signs Agreement to Sell the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System to AbbVie

WST

Jan 12, 2026, 5:12 AM EST - 20 days ago

Dividend Income: Lanny's November 2025 Summary

AFL CAT COF CVS CZNC EMR ETN

Jan 10, 2026, 9:30 AM EST - 21 days ago

MoneyShow's Best Investment Ideas For 2026: Part 1

ABR ACHR ARE ARES ARMN ASTS

Jan 8, 2026, 12:07 PM EST - 23 days ago

AbbVie: The Dividend Does Not Lie

Jan 8, 2026, 7:38 AM EST - 24 days ago

AbbVie Denies It's in Talks to Buy Revolution Medicines. Both Stocks Are Falling.

RVMD

Jan 7, 2026, 2:58 PM EST - 24 days ago

AbbVie in talks to buy biotech Revolution Medicines, WSJ reports

RVMD

Jan 7, 2026, 2:48 PM EST - 24 days ago

AbbVie Near Deal for Revolution Medicines

RVMD

Jan 7, 2026, 8:00 AM EST - 25 days ago

AbbVie to Host Full-Year and Fourth-Quarter 2025 Earnings Conference Call

Jan 6, 2026, 11:43 AM EST - 25 days ago

What Can Trigger A Breakout In Abbvie Stock?

Jan 6, 2026, 7:29 AM EST - 26 days ago

Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month

ARGX NBIX

Jan 5, 2026, 8:00 AM EST - 27 days ago

AbbVie to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 4, 2026, 9:04 AM EST - 4 weeks ago

AbbVie: Rocky Near-Term, Positive Long-Term

Jan 3, 2026, 7:30 AM EST - 4 weeks ago

My Most Important Warning To Dividend Investors For 2026

AM ARES CNI CPT ENB EPD EXR

Jan 1, 2026, 10:24 PM EST - 4 weeks ago

AbbVie: Solid Growth, Some Risks, And An Attractive Setup In 2026

Dec 31, 2025, 8:47 AM EST - 4 weeks ago

Best Dividend Aristocrats For January 2026

ABT ADM ADP AFL ALB AMCR AOS

Dec 28, 2025, 6:44 AM EST - 5 weeks ago

Best Dividend Kings: December 2025

ABM ABT ADM ADP AWR BDX BKH

Dec 19, 2025, 10:45 AM EST - 6 weeks ago

Trump to announce new drug-pricing deals later today

AMGN AZN BMY GILD LLY MRK NVO

Dec 17, 2025, 4:11 PM EST - 6 weeks ago

AbbVie, several other pharma companies near MFN deal with Trump, sources say

AMGN AZN BMY LLY NVS PFE

Dec 17, 2025, 2:17 PM EST - 6 weeks ago

Final Trades: Abbvie Inc, Microsoft, Netflix and Twilio Inc

MSFT NFLX TWLO

Dec 14, 2025, 11:30 PM EST - 6 weeks ago

AMG Frontier Small Cap Growth Fund: Q3 Sees Strong Outperformance Across Semiconductor Holdings

ALGT CGNX COHR EOLS INSP LTH MAT

Dec 10, 2025, 8:01 PM EST - 7 weeks ago

AbbVie: Unique Mix Of Growth And Value

Dec 8, 2025, 1:30 AM EST - 7 weeks ago

OSE Immunotherapeutics Announces Strategic Amendment to AbbVie's Partnership on ABBV-230 Development

Dec 3, 2025, 4:53 PM EST - 2 months ago

AbbVie Inc. (ABBV) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Dec 2, 2025, 8:15 AM EST - 2 months ago

AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers

Dec 1, 2025, 5:55 AM EST - 2 months ago

AbbVie: Increased Outlook For 2025 And Expansions Merit Continued "Strong Buy" Rating

Nov 29, 2025, 8:02 AM EST - 2 months ago

Best Dividend Aristocrats For December 2025

ABT ADM ADP AFL ALB AMCR AOS

Nov 28, 2025, 7:01 AM EST - 2 months ago

SKYRIZI® (risankizumab) Receives Positive Reimbursement Recommendation by Canada's Drug Agency for Ulcerative Colitis and AbbVie Concludes Letter of Intent with the pan-Canadian Pharmaceutical Alliance

Nov 25, 2025, 9:30 AM EST - 2 months ago

AbbVie and adMare BioInnovations Foster Life Sciences Innovation with the Launch of the AbbVie Biotech Innovators Award in Quebec

Nov 24, 2025, 8:00 AM EST - 2 months ago

AbbVie to Present at the Piper Sandler 37th Annual Healthcare Conference

$AbbVie Announces U.S. FDA Approval of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma$

Nov 18, 2025, 12:47 PM EST - 2 months ago

AbbVie Announces U.S. FDA Approval of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma

dewmoore Feb. 1 at 1:19 PM

3 · Reply

crtlabz Feb. 1 at 2:53 AM

$ABBV pipeline and growth accelerating. Been here 17y and don't mind the income. Divvy could be better, but better fundementals are the focus.

1 · Reply

DM1963 Jan. 31 at 6:44 PM

$ABBV Wow this stock was 60 during Covid expectations high would be nice to see them lower

0 · Reply

JFDI Jan. 30 at 8:44 PM

$ABBV

0 · Reply

ChessGM Jan. 30 at 7:59 PM

$ABBV https://youtu.be/h-s8MagQo1k. My focus list for stocks reporting earnings next week.

0 · Reply

taxplanr Jan. 30 at 5:49 PM

$ABBV not a bad yield for $110

0 · Reply

Sunny3999 Jan. 30 at 2:10 PM

0 · Reply

Sunny3999 Jan. 30 at 1:13 PM

0 · Reply

dogDazeSummer Jan. 29 at 10:55 PM

1 · Reply

scottybebs Jan. 29 at 9:15 PM

$ABBV what was that close!?

1 · Reply

Buster67 Jan. 29 at 6:30 PM

$ABBV Sellers showing hesitation

0 · Reply

clan Jan. 29 at 5:03 AM

$NVS $ABBV $RHHBY Who here knew there is an INHALABLE mealtime insulin?!? Holy smokes! 😲 No shooting up at meals! ❤️

0 · Reply

WallStreetBuyDip Jan. 28 at 9:45 PM

$ABBV Trading around $220, bouncing off recent lows near $170. Bulls struggling to break above $245 resistance level in the past. Volume showing some decline in recent sessions.

0 · Reply

LongJohnOption Jan. 28 at 7:59 PM

$ABBV well, just losing everything in one day cool

0 · Reply

Sunny3999 Jan. 28 at 7:31 PM

$PMN hidden gem 💎 ready to rip! https://www.promisneurosciences.com/investors/news-events/press-releases/detail/246/promis-neurosciences-granted-fast-track-designation-by-u-s $ABBV $BMY $MRK $SNY

0 · Reply

mydogabbymoon Jan. 28 at 6:52 PM

$ABBV 400b company trading like a meme stock since CEO change

0 · Reply

FRAGMENTS Jan. 28 at 6:51 PM

$PDYN $UNH $ABBV $JNJ

0 · Reply

Sunny3999 Jan. 28 at 6:32 PM

$PMN Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk https://www.promisneurosciences.com/investors/news-events/press-releases/detail/259/promis-neurosciences-announces-new-peer-reviewed $ABBV $BMY $MRK $SNY

0 · Reply

Sunny3999 Jan. 28 at 5:47 PM

$PMN Ready to rip! From last PR: “This is a major execution milestone for ProMIS and a potentially pivotal moment for the Alzheimer’s field” said Neil Warma, Chief Executive Officer of ProMIS Neurosciences. “Completing enrollment and above our target in a rigorously designed, biomarker-rich study of this scale positions us to potentially confirm, clinically and biologically, for the first time the central role of toxic amyloid-beta oligomers in Alzheimer’s disease. The safety profile we have observed thus far, with no treatment-related SAEs and minimal dropouts, reinforces our belief that PMN310 may offer a fundamentally differentiated approach that has the potential to significantly reduce the ARIA liability that has limited broader use of current therapies. We believe the over-enrollment of PRECISE-AD may reflect strong enthusiasm among both patients and trial physicians for PMN310’s differentiated mechanism and its potential for improved safety $ABBV $BMY $MRK $PMN $SNY

0 · Reply

Oldpuck Jan. 28 at 5:06 PM

$ABBV Any idea for the hit today, most of pharma is down but lately ABBV seems to get hit the hardest. Is it Medicare/Medicaid pricing?

0 · Reply

scottybebs Jan. 28 at 4:35 PM

$ABBV this is silly

0 · Reply

LongJohnOption Jan. 28 at 3:35 PM

$ABBV giving it all back

0 · Reply

Market Cap	394.14B
Revenue (ttm)	56.33B
Net Income (ttm)	4.28B
EPS (ttm)	N/A
PE Ratio	23.33
Forward PE	15.39
Profit Margin	7.59%
Debt to Equity Ratio	-26.45

Volume	6,622,200
Avg Vol	6,203,478
Day's Range	N/A - N/A
Shares Out	1.77B
Stochastic %K	77%
Beta	0.36
Analysts	Strong Sell
Price Target	$245.80